Vycor Medical Inc. has reported its financial results for the three and six months ending June 30, 2025. The company experienced a notable increase in revenue, with the Vycor Medical division seeing a 24% rise in revenue for the three-month period and a 28% increase for the six-month period, primarily driven by growth in international markets. For the three months ended June 30, 2025, Vycor Medical reported revenue of $496,353, up from $406,278 in the same period of 2024. The gross profit for the same period rose to $415,271 from $371,115. For the six months ended June 30, 2025, revenue increased to $932,731 compared to $743,246 in the prior year, with gross profit rising to $773,805 from $671,077. The company posted a GAAP net income of $23,887 for the three-month period, with an operating profit of $51,146. Vycor Medical's non-GAAP operating profit for the same period was $84,481, reflecting a significant increase over the 2024 periods. Vycor Medical has also expanded its international presence by entering into new distribution agreements for France and Spain during the first half of 2025, identifying these as key markets for further international expansion. No specific outlook or guidance was provided in the release.